Assenagon Asset Management S.A. Reduced Its Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART).

3 min read | January 24, 2025 01:02 AM PST | By Team Kalkine Media

Assenagon Asset Management S.A. Reduced Its Stock Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART).

Market Overview and Investment Activities

Assenagon Asset Management S.A. has reduced its position in Integra LifeSciences Holdings Co.(NASDAQ:IART) by 22.8% during the fourth quarter, as disclosed in the latest SEC filings. The management firm now holds 71,464 shares after divesting 21,053 shares during this period. As of this filing, Assenagon Asset Management owns about 0.09% of Integra LifeSciences, valued at approximately $1.62 million.

Other institutional players have also made notable moves in Integra LifeSciences. Notably, Sachem Head Capital Management LP acquired a substantial new stake in the third quarter, valued at about $44.15 million. Dimensional Fund Advisors LP and Charles Schwab Investment Management Inc. increased their stakes modestly, while D. E. Shaw & Co. Inc. significantly bolstered its position by 64.6%. Glenmede Trust Co. NA expanded its holdings dramatically in the third quarter, marking a growth of 125.9%.

Stock Performance Insights

On the market, Integra LifeSciences' shares opened at $25.60, showcasing a 3.0% increase. With financial ratios including a quick ratio of 0.73 and a current ratio of 1.20 alongside a debt-to-equity ratio of 0.79, the company demonstrates a stable liquidity position. Despite a negative net margin of 0.42%, the company reported a positive return on equity of 12.35%.

Analyzing its recent quarterly performance, the company surpassed consensus estimates with an earnings per share (EPS) of $0.41, exceeding predictions by $0.02. However, revenue experienced a slight downturn of 0.4% compared to the same quarter of the previous year.

Institutional and Insider Activities

Insiders also have played active roles, with transactions such as Executive VP Michael J. Mcbreen selling 1,700 shares in December. His sale, at an average price of $24.16, amounted to a total transaction value of $41,072. Now holding 56,182 shares, Mcbreen’s adjustment reflects a brief contraction in his investment, decreasing by approximately 2.94%.

Analyst Ratings and Sector Positioning

Research notes have seen price targets vary significantly, influenced by market trends and company developments. Although some analysts have suggested caution with sell ratings, others propose a neutral stance, highlighting nuanced perspectives on Integra LifeSciences’ market position.

Integra LifeSciences Holdings Corporation actively develops and markets medical devices for critical care and surgical applications. Operating through its Codman Specialty Surgical and Tissue Technologies segments, the company offers extensive product lines that serve neurosurgery and related specialties.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.